94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1462249
This article is part of the Research Topic Disease-modifying approaches in type 1 diabetes View all 12 articles
The partial clinical remission phase of type 1 diabetes: early-onset dyslipidemia, long-term complications, and disease-modifying therapies
Provisionally accepted- Donald and Barbara Zucker School of Medicine, Hofstra University, Hempstead, United States
A literature search was conducted to identify publications addressing the partial clinical remission phase of type 1 diabetes with an emphasis on early lipid phenotypes in both children and adults with either type 1 diabetes or type 2 diabetes. We searched Medline, EMBASE, and Ovid using the following search terms: lipids, disease-modifying therapies, honeymoon phase, clinical remission, partial remission, partial clinical remission, C-peptide, type 1 or 2 diabetes, children, pediatric type 1 or 2 diabetes, and paediatrics type 1 or 2 diabetes, adults, adult type 1 or type 2 diabetesPart I. Introduction and scope Part II: Proposed theories to explain the partial clinical remission phase of type 1 diabetes; and the comparison of the magnitude of early-onset dyslipidemia in both type 1 and type 2 diabetes Part III: The case for PR-mediated hyperlipidemic memory as the primary determinant of early lipid phenotypes in both pediatric and adult type 1 diabetes Part IV: Conclusions and future directions on disease-modifying therapies in type 1 diabetes to limit atherosclerotic cardiovascular disease risk
Keywords: type 1 diabetes, type 2 diabetes, Dyslipidemia, hyperglycemic memory, hyperlipidemic memory, Honeymoon phase, partial clinical remission
Received: 09 Jul 2024; Accepted: 03 Mar 2025.
Copyright: © 2025 Nwosu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Benjamin Udoka Nwosu, Donald and Barbara Zucker School of Medicine, Hofstra University, Hempstead, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.